Oxford BioMedica PLC

142 articles with Oxford BioMedica PLC

• Oxford BioMedica PLC To Participate At Piper Jaffray Genomerx Symposium In New York On 23 June 2014

  6/20/2014

• Oxford BioMedica PLC Results Of Firm Fundraising And Open Offer

  6/16/2014

• Oxford BioMedica PLC Completes Patient Recruitment Into Retinostat® Phase I Trial

  4/7/2014

• Oxford BioMedica PLC And Sanofi (France) Amend Terms For Ocular Licence

  2/17/2014

• Oxford BioMedica PLC Announces Publication Of ProSavin® Phase I/II Study in The Lancet

  1/10/2014

• Oxford BioMedica PLC Announces Option Agreement With GlaxoSmithKline

  12/18/2013

• Oxford BioMedica PLC Interim Management Statement

  11/19/2013

• Oxford BioMedica PLC Announces £5 Million Loan Facility From Lead Shareholder Vulpes Life Sciences Fund

  11/19/2013

• Oxford BioMedica PLC Receives Agreement From FDA and ANSM to Resume Recruitment Into Ocular Clinical Trials

  10/17/2013

• Oxford BioMedica PLC Wins Significant Funding Via a Competitive Award From UK Government's Advanced Manufacturing Supply Chain Initiative

  9/11/2013

• Oxford BioMedica PLC Release: Interim Results for the Six Months Ended 30 June 2013

  8/29/2013

• Oxford BioMedica PLC Announces $1 Million Milestone Payment From Pfizer Inc.

  8/28/2013

• Oxford BioMedica PLC Announces Update From Association for Research in Vision & Ophthalmology 2013

  5/9/2013

• Oxford BioMedica PLC Abandons Prostate Cancer Vaccine Study

  10/11/2012

• Oxford BioMedica PLC to Present at Conference

  8/29/2012

• Oxford BioMedica PLC Announces Positive DSMB Review of Ongoing RetinoStat&#0174 and StarGen&#0153 Clinical Studies

  8/8/2012

• Oxford BioMedica PLC Receives Funding Award From the Foundation Fighting Blindness for ongoing UshStat&#0174 Phase I/IIa study

  7/23/2012

• Oxford BioMedica PLC Announces Initiation of Phase II Collaborative Study for TroVax&#0174 in Colorectal Cancer

  7/11/2012

• Oxford BioMedica PLC Announces Research and Development Collaboration for Glaucoma

  10/31/2011

• Oxford BioMedica PLC Announces US IND Approval for Novel Ocular Product in Usher Syndrome Type 1B

  10/18/2011